Virchows Archiv

, Volume 450, Issue 6, pp 665–670 | Cite as

Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies

  • Simone Schmid
  • Milos Opravil
  • Michael Moddel
  • Milo Huber
  • Rahel Pfammatter
  • Gerald Keusch
  • Patrice Ambuhl
  • Rudolf P. Wuthrich
  • Holger Moch
  • Zsuzsanna Varga
Original Article

Abstract

We performed a retrospective analysis on kidney biopsies of 30 human immunodeficiency virus (HIV)-positive patients. Twenty-two of them received highly active antiretroviral therapy (HAART). Tenofovir containing HAART together with atazanavir, a new protease inhibitor, was administered to three patients. All of them developed acute renal failure. The kidney biopsies of these patients showed an acute interstitial nephritis or a chronic interstitial nephritis with an acute component. Withdrawal of atazanavir and tenofovir resulted in recovery of renal function in all three patients. Acute interstitial nephritis was observed only in 1 of 19 patients without atazanavir or tenofovir treatment. We conclude that acute interstitial nephritis and consecutive acute renal failure is a relevant side effect of atazanavir and tenofovir therapy in HIV-positive patients.

Keywords

HIV Interstitial nephritis Kidney biopsy Atazanavir 

Notes

Acknowledgments

The technical assistance of Mrs. Juliane Bigott and Mrs. Doris Guntersweiler is highly appreciated. Mr. N. Wey helped in the illustration. The study complies with the current ethical laws of the involved institutions.

References

  1. 1.
    Brewster UC, Perazella MA (2004) Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 44:e81–e84PubMedCrossRefGoogle Scholar
  2. 2.
    Cho ME, Kopp JB (2004) HIV and the kidney: a status report after 20 years. Curr HIV/AIDS Rep 1:109–115PubMedCrossRefGoogle Scholar
  3. 3.
    D’Agati V, Appel GB (1998) Renal pathology of human immunodeficiency virus infection. Semin Nephrol 18:406–421PubMedGoogle Scholar
  4. 4.
    D’Agati V, Jennette J, Silva F (2005) Non-neoplastic kidney diseases. ARP Press, Silver Spring, MDGoogle Scholar
  5. 5.
    European Medicines Agency (2006) http://www.emea.eu.int/humandocs/PDFs/EPAR/viread/351001en8b.pdf; accessed on 8 Mar 2007
  6. 6.
    Fogo A, Kashgarian M (2005) Diagnostic atlas of renal pathology, 1st edn. Elsevier, SaundersGoogle Scholar
  7. 7.
    Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O’Mara E (2005) Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. Aids 19:1635–1641PubMedCrossRefGoogle Scholar
  8. 8.
    Fux C, Simcock M, Wolbers M, Bucher H, Cavassini M, Opravil M, Vernazza P, Hirschel B, Bernasconi E, Furrer H, Swiss HIV Cohort Study S (2007) Tenofovir treatment is associated with a decrease in calculated glomerular filtration rates in a large observational cohort. In: 14th Conference on retroviruses and opportunistic infections, Los Angeles, USA, 25–28 FebruaryGoogle Scholar
  9. 9.
    Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, California Collaborative Treatment Group CT (2007) Increased renal impairment in patients receiving TDF+PI vs TDF+NNRTI. In: 14th Conference on retroviruses and opportunistic infections, Los Angeles, USA, 25–28 FebruaryGoogle Scholar
  10. 10.
    Hailemariam S, Walder M, Burger HR, Cathomas G, Mihatsch M, Binswanger U, Ambuhl PM (2001) Renal pathology and premortem clinical presentation of Caucasian patients with AIDS: an autopsy study from the era prior to antiretroviral therapy. Swiss Med Wkly 131:412–417PubMedGoogle Scholar
  11. 11.
    Han TM, Naicker S, Ramdial PK, Assounga AG (2006) A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 69:2243–2250PubMedCrossRefGoogle Scholar
  12. 12.
    Izzedine H, Launay-Vacher V, Peytavin G, Valantin MA, Deray G (2005) Atazanavir: a novel inhibitor of HIV-protease in haemodialysis. Nephrol Dial Transplant 20:852–853PubMedCrossRefGoogle Scholar
  13. 13.
    Jennette JC, Olson JL, Schwartz M, Silva F (2007) Heptinstall’s pathology of the kidney, 6th edn. Lippincott Williams & WilkinsGoogle Scholar
  14. 14.
    Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM (2003) Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36:1070–1073PubMedCrossRefGoogle Scholar
  15. 15.
    Kern W, Laszik Z, Nadasdy T, Silva F, Bane B, Pitha J (1999) Atlas of renal pathology. Saunders, PhiladelphiaGoogle Scholar
  16. 16.
    Kim RJ, Wilson CG, Wabitsch M, Lazar MA, Steppan CM (2006) HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 14:994–1002CrossRefGoogle Scholar
  17. 17.
    Moddel M, Pfammatter R, Varga Z, Keusch G (2006) Acute tubulointerstitial nephritis in HIV infection. Schweiz Rundsch Med PRAXIS 95:949–951Google Scholar
  18. 18.
    Panel on Antiretroviral Guidelines for Adult and Adolescents (2006) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, October 10, 2006. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed 8 Mar 2007, pp 1–113
  19. 19.
    Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Ceron D (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35:269–273PubMedCrossRefGoogle Scholar
  20. 20.
    Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD (2006) HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 42:1488–1495PubMedCrossRefGoogle Scholar
  21. 21.
    Scott JD, Wolfe PR, Bolan RK, Guyer B (2006) Serious renal impairment occurs rarely with use of tenofovir DF. HIV Clin Trials 7:55–58PubMedCrossRefGoogle Scholar
  22. 22.
    Striker G, Striker L, D’Agati V (1997) The renal biopsy, 3rd edn. SaundersGoogle Scholar
  23. 23.
    Szeto CC, Chow KM (2005) Nephrotoxicity related to new therapeutic compounds. Ren Fail 27:329–333PubMedCrossRefGoogle Scholar
  24. 24.
    Valle R, Haragsim L (2006) Nephrotoxicity as a complication of antiretroviral therapy. Adv Chronic Kidney Dis 13:314–319PubMedCrossRefGoogle Scholar
  25. 25.
    Wyatt CM, Klotman PE (2006) Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf 5:275–287PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Simone Schmid
    • 1
  • Milos Opravil
    • 2
  • Michael Moddel
    • 3
  • Milo Huber
    • 2
  • Rahel Pfammatter
    • 3
  • Gerald Keusch
    • 3
  • Patrice Ambuhl
    • 4
  • Rudolf P. Wuthrich
    • 4
  • Holger Moch
    • 1
  • Zsuzsanna Varga
    • 1
  1. 1.Department of Pathology, Institute of Surgical PathologyUniversity Hospital ZurichZurichSwitzerland
  2. 2.Department of Internal Medicine, Division of Infectious DiseasesUniversity Hospital ZurichZurichSwitzerland
  3. 3.Department of NephrologyCity Hospital WaidZurichSwitzerland
  4. 4.Clinic of NephrologyUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations